Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Current Pharmaceutical Design|April 14, 2004
Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetesAllan S Wagman, Kirk W Johnson, Dirksen E Bussiere
Headache|April 16, 2019
CGRP and the Trigeminal System in MigraineSmriti Iyengar, Kirk W Johnson, Michael H Ossipov, et al.
Neuroscience Letters|June 15, 2005
Systemic administration of propentofylline does not attenuate morphine tolerance in non-injured rodentsJennifer A Shumilla, Isa Samuels, Kirk W Johnson, et al.
European Journal of Pharmacology|April 20, 2010
The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapsePatrick M Beardsley, Keith L Shelton, Elizabeth Hendrick, et al.
Expert Opinion on Investigational Drugs|June 28, 2007
Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromesAnnemarie Ledeboer, Mark R Hutchinson, Linda R Watkins, et al.
Cephalalgia : an International Journal of Headache|April 21, 2019
Peripheral and central nervous system distribution of the CGRP neutralizing antibody [<sup>125</sup>I] galcanezumab in male ratsKirk W Johnson, S Michelle Morin, Victor J Wroblewski, et al.
Pageof 7